This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

About NVAFAbout NVAFNICE Guideline recommendationsImplementing NICE GuidelinesDetection and DiagnosisAbout EliquisAbout Eliquis (apixaban)About EliquisPatient Information bookletsSupporting ResourcesSupporting ResourcesMaterialsVideos

Click here for Eliquis® (apixaban) Prescribing Information. Adverse event reporting information can be found at the bottom of the page. Eliquis is co-promoted with Bristol-Myers Squibb.

 Cardiovascular disease remains the biggest cause of   premature mortality and the rate of improvement has   slowed1

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Non-valvular atrial fibrillation (NVAF) is a common heart arrhythmia, affecting one in 20 people over the age of 65 and one in ten over the age of 755.
Cardiovascular disease is the single biggest condition where the  NHS can save lives over the next 10 years1
 Header of this card goes here
Stroke,
a preventable cardiovascular disease, is the fourth single leading cause of death in the UK and the single largest cause of complex disability1
 Button Loading

Optional footnote area for disclaimers etc.

 ​​​​​BadgeBadgeBadgeNavigationNICE Guideline recommendations

Learn more about 2021 NICE Guideline (NG196) anticoagulation recommendations for stroke prevention in NVAF.

Learn moreLoadingDetection & Diagnosis

Find out more about 'DETECT': A national initiative to find individuals undiagnosed with AF who are at risk of AF-related stroke.

Discover moreLoading
Our brand - Eliquis (apixaban)

ELIQUIS – an oral, direct factor Xa inhibitor – is indicated for:
 

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II).

Explore EliquisLoadingNHS, National Health Service.
  1. NHS. The NHS Long Term Plan. 2019. Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf;
  2. NI Department of Health. Service Framework for Cardiovascular Health and Wellbeing. 2016. Available at: https://www.health-ni.gov.uk/publications/cardiovascular-health-and-well-being-service-framework-documents;
  3. NHS Wales and the Welsh Government. 2017–2020 Stroke Delivery Plan. Available at: https://gov.wales/sites/default/files/publications/2018-12/stroke-delivery-plan-2017-to-2020.pdf;
  4. NHS National Services Scotland. Scottish Stroke Improvement Programme. 2019. Available at: https://www.strokeaudit.scot.nhs.uk/Publications/docs/2019/Scottish-Stroke-Improvement-Programme-2019-National-Report.pdf. All websites accessed May 2022.
  5. Hankey GJ. Non-valvular atrial fibrillation and stroke prevention. Medical Journal of Australia. 2001;174:234–239 Available at: https://pubmed.ncbi.nlm.nih.gov/11280695/ Accessed April 2022
PP-ELI-GBR-10851. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​